Sentences with phrase «new funding programs»

Also at the forefront of scientific change is the National Institutes of Health (NIH), which is introducing new funding programs in bioinformatics.

First encouraging approaches, such as new funding programs for young scientists that try to soften the dependence on the traditional faculty hierarchy, have been launched by the Deutsche Forschungsgemeinschaft and the Volkswagen - Stiftung.

Canadian CEOs are hopeful that new funding programs like the Venture Technologies Fund will help more Ontario - based firms access capital, so they can continue to scale up globally.»

The U.S. Centers for Disease Control and Prevention announced a new funding program to help increase the numbers of underrepresented minorities in biostatistics and related fields.

Some European researchers are pushing for the idea of not only strengthening the ERC but also modeling more of the rest of the new funding program on it.

Q: You've said several times that the new funding program will be a «radical departure,» a «clean break» from the Framework Programmes.

Not exact matches

The animosity, which the Wall Street titan saw fueling the possibility of a U.S. - China war, led him to double down on his new immersive scholarship program, Schwarzman Scholars, which he funded with a $ 100 million donation.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Netflix is currently exempted from CanCon rules, which include funding and programming requirements, thanks to a special new media clause.

Last year at the Cannes Lions advertising festival, Nadal awarded $ 1 - million startup funding for an advanced program in New York called the Digital Works Institute.

With programs like the Domain competition, Idea Village, Launch Pad, and the New Orleans Startup Fund, New Orleans is building a reputation as an under - the - radar location for young entrepreneurs.

Still, by closing the program to new funds, the SBA, by its own admission, has «removed the primary method by which [it] can provide access for small businesses to equity capital.»

It was 1997, and the headstrong trader had just launched a new hedge fund backed by a proprietary computer program that he believed could cut through the chaos of the market and reveal truths invisible to the rest of Wall Street.

How long will the additional money be able to fund these new programs?

Bankwest today launched its new charity, which will raise funds for community initiatives, as well as a scholarship program that aims to better the lives of Western Australians, and has pledged $ 1 million per year to the charity for five years.

Amazon has suspended part of its expansion plans in Seattle, pending the outcome of a City Council vote on a new tax on large employers that would fund programs aimed at providing affordable housing and helping the homeless.

Vice says it will use the new funds for programming and international expansion.

Online streaming service provider Quickflix has requested a trading halt for at least a month so it can undertake a restructuring program aimed at reducing costs, raising funds and attracting new customers.

«Since our company isn't one with much capital — our «assets» are our employees and contracts — we have been able to finance new programs under an accounts receivable margining system, in which the bank will loan us short - term funds based on our current contracts and receivables.

«This program was supposed to make sure credit flowed to Main Street,» Republican Sen. Charles Grassley recently noted, «but instead it has been used as a slush fund to pick winners and losers in New York and Detroit.

As well, they can participate in the Student Investment Fund, where students in the second year of the program help manage a portion of New Brunswick's pension fFund, where students in the second year of the program help manage a portion of New Brunswick's pension fundfund.

WASHINGTON, April 19 - The United States and Colombia on Thursday cited new evidence of fraud in Venezuela's food import program for the needy, saying part of the funds often ended up in the hands of corrupt government officials after being funneled through businesses in nearby countries.

If the government were to structure its new $ 400 - million program as a coinvestment fund, as is available in several U.S. states and Canadian provinces, three important outcomes are guaranteed.

«If we don't act, in the next five years we'll be saying the same things: that Greece isn't going well, that there are no jobs... that we have a new program by the International Monetary Fund and European Union to support us,» the 25 - year - old said.

WASHINGTON, March 26 - Federal Communications Commission Chairman Ajit Pai on Monday said he was proposing new rules to bar the use of funds from a government program to purchase equipment or services from companies that pose a security threat to U.S. communications networks.

If the new administration really wants to restore U.S. manufacturing, fix the trade deficit, and boost innovation, it should leverage the best ideas that come from federal research programs and invest in funding the next big thing.

And in 2010, lack of funding and new government priorities forced NASA to shut down its Constellation program which was working on a rocket designed to take us back to the moon and beyond.

A local community development financial institution used a state program to fund energy - efficient upgrades, including new windows, light fixtures, furnaces and siding.

Boston and Washington, D.C., for example, use a mix of federal, state, and city money to fund their programs, while New York City's bike - sharing initiative is financed entirely by private means.

In both cases, social programs — whether it was FDR's New Deal, which created unemployment insurance and institutionalized unions, or the G.I. Bill, which funded post-secondary employment for soldiers — stemmed the rising tide.

We improved accessibility through the Enabling Accessibility Fund, provided new investments for people with disabilities to join and contribute to the workforce, and helped improve access to financial independence through programs such as the Registered Disabilities Savings Plan (RDSP).

New funds for the program would need to be raised at an international summit in Brussels in October.

Netflix CEO Reed Hastings has touted the «virtuous cycle» where new subscriber growth funds more program spending, which attracts even more subscribers.

A NEW Federal Government - funded program will help small to medium enterprises take advantage of international trade on the Internet.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

We own a number of these carriers in our funds: Delta Air Lines (which announced a $ 5 - billion stock buyback program in May), Alaska Air, and JetBlue in the Holmes Macro Trends Fund (MEGAX); Ryanair (which just hit a new 52 - week high) and Aegean Greece in the Emerging Europe Fund (EUROX).

Part of the proceeds of the new fundraising will be dedicated to a new fund for the production of scripted programming, one of many strands of content creation into which the at times controversial company is expanding.

Seattle is considering imposing a new 0.7 % payroll tax on large employers to fund affordable housing programs and reduce homelessness.

The new program would see the Ontario government pledging to fund the cost of full - day, licensed child care starting once children turn two - and - a-half

To learn more about our Corporate Programs, New Venture Creation and Investment Funds, visit the Highline BETA website

Aya Zook is a Principal at Microsoft Ventures, responsible for managing marketing and PR, and is passionate about building new initiatives designed to source and engage promising early stage startups for the fund program.

Passionate about the University of Calgary, Schmidt and Laricina Energy Ltd. both played pivotal roles in the Engineering Leaders Campaign at the Schulich School of Engineering, funding a five - year scholarship program, a chemical and petroleum engineering graduate student space, a boardroom in the new engineering building expansion, and a portion of the Canada Research Chair in Energy and Imaging.

What do you make of Bank of America's new Affordable Loan Program, which offers 3 % - down mortgages with no mortgage insurance, and partners with Freddie Mac in something called the Self - Help Ventures Fund?

A percentage of every nomination fee, seal licensing fee, and gala ticket is a tax deductible contribution used to help tell the broader story of innovation, advance the values and principles of Thomas A. Edison and other accomplished innovators, to fund programs and conferences dedicated to innovation and education, and to fund the development of new innovation curricula.

The new funding will be directed to increase income assistance, funding for anti-poverty initiatives, and to address pressures in the Senior Citizen and Disabled Persons Property Tax Relief Program and the Territorial Power Subsidy Program.

With the new funds totaling $ 15 million, Better Mortgage will expand a nascent program of offering homeowners a guaranteed interest rate within 20 minutes of filling out an online application, said Chief Executive Vishal Garg.

That being said, the fate of PSLF has been up in the air lately, and it's unclear whether the government will continue to fund the program for new applicants.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

With the ending of the stimulus funding and the repayment of the principal on assets maturing under the Insured Mortgage Purchase Program, the federal government's new borrowing requirements are falling dramatically.

The 1999 Budget included new funding to address «health and safety» issues resulting from the measures taken in the 1995 Program Review Exercise.